Amylin Pharmaceuticals Inc. (AMLN: News ) and Eli Lilly and Co. (LLY: News ) said the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has issued a positive opinion in the European Union or EU for the expanded use of BYETTA as an add-on therapy to basal insulin, with or without metformin and/or Actos, for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. The CHMP’s decision is now referred for final action to the European Commission, which usually decides on CHMP recommendations within two to three months.
